Embryonal Childhood Rhabdomyosarcoma
8
0
0
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
25%
2 trials in Phase 3/4
13%
1 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (8)
Retrospective Study in FFPE Samples From Younger Patients With Rhabdomyosarcoma
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Studying Mechanisms of Radiation Therapy Resistance in Samples From Younger Patients With Rhabdomyosarcoma
Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma
Studying Protein Expression in Tissue Samples From Younger Patients With Rhabdomyosarcoma
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma
Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma